Effect of enhanced external counterpulsation treatment on renal function in cardiac patients

BMC Nephrology

Thanom Supaporn⁴  Anchalee Chittamma²  Somlak Vanavanan²  Dollapas Punpanich⁴  Surawat Adirekkiat¹  Amnart Chaiprasert⁴  Chagriya Kitiyakara³  Piyanuj Ruckpanich⁵  Ongkarn Raungratanaamporn⁵  Nithi Mahanonda⁵  Prajej Ruangkanchanasetr⁴ 

[1] Division of Nephrology, Department of Medicine, Piyavate Hospital, Bangkok, Thailand;Division of Clinical Chemistry, Department of Pathology, Ramathibodi Hospital, Bangkok, Thailand;Division of Nephrology, Department of Medicine, Ramathibodi Hospital, Bangkok, Thailand;Division of Nephrology, Department of Medicine, Phramongkutklao Hospital, 315 Rajavithi Road, Rajathevi, Bangkok 10400, Thailand;Perfect Heart Institute, Piyavate Hospital, Bangkok, Thailand

关键词: Heart failure;    Glomerular filtration rate;    Cystatin C;    Chronic kidney disease;    Angina;   

Others  :  1082846
DOI  :  10.1186/1471-2369-14-193

 received in 2013-02-11, accepted in 2013-09-04,  发布年份 2013

【 摘 要 】

Background

Enhanced external counterpulsation (EECP) enhances coronary perfusion and reduces left ventricular afterload. However, the role of EECP on renal function in cardiac patients is unknown. Our aim was to assess renal function determined by serum cystatin C in cardiac patients before and after EECP treatment.

Methods

A prospective observational longitudinal study was conducted in order to evaluate renal function using serum cystatin C (Cys C) and estimated glomerular filtration rate (GFR) after 35 sessions of EECP treatment in 30 patients with chronic stable angina and/or heart failure. The median (IQR) time for follow-up period after starting EECP treatment was 16 (10–24) months.

Results

Cys C significantly declined from 1.00 (0.78-1.31) to 0.94 (0.77-1.27) mg/L (p < 0.001) and estimated GFR increased from 70.47 (43.88-89.41) to 76.27 (49.02-91.46) mL/min/1.73 m² (p = 0.006) after EECP treatment. Subgroup analysis showed that patients with baseline GFR <60 mL/min/1.73 m² or NT-proBNP >125 pg/mL had a significant decrease in Cys C when compared to other groups (p < 0.01).

Conclusions

The study demonstrated that EECP could improve long-term renal function in cardiac patients especially in cases with declined renal function or with high NT-proBNP.

Trial registration

The study was registered in the clinical trial as International Standard Randomized Controlled Trial Number ISRCTN11560035.

【 授权许可】

   
2013 Ruangkanchanasetr et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

【 参考文献 】

• [1]Ronco C, Haapio M, House AA, Anavekar N, Bellomo R: Cardiorenal syndrome. J Am Coll Cardiol 2008, 52:1527-1539.
• [2]Anavekar NS, McMurray JJV, Velazquez EJ, Solomon SD, Kober L, Rouleau JL, White HD, Nordlander R, Maggioni A, Dickstein K, Zelenkofske S, Leimberger JD, Califf RM, Pfeffer MA: Relation between renal dysfunction and cardiovascular outcomes after myocardial infarction. N Engl J Med 2004, 351:1285-1295.
• [3]Hillege HL, Nitsch D, Pfeffer MA, Swedberg K, McMurray JJV, Yusuf S, Granger CB, Michelson EL, Östergren J, Cornel JH, de Zeeuw D, Pocock S, van Veldhuisen DJ: Renal function as a predictor of outcome in a broad spectrum of patients with heart failure. Circulation 2006, 113:671-678.
• [4]Arora RR, Chou TM, Jain D, Fleishman B, Crawford L, McKiernan T, Nesto RW: The multicenter study of enhanced external counterpulsation (MUST-EECP): effect of EECP on exercise-induced myocardial ischemia and angina episodes. J Am Coll Cardiol 1999, 33:1833-1840.
• [5]Michaels AD, McCullough PA, Soran OZ, Lawson WE, Barsness GW, Henry TD, Linnemeier G, Ochoa A, Kelsey SF, Kennard ED: Primer: practical approach to the selection of patients for and application of EECP. Nat Clin Pract Cardiovasc Med 2006, 3:623-632.
• [6]Conti CR: EECP-enhanced external counterpulsation. J Am Coll Cardiol 1999, 33:1841-1842.
• [7]Mielniczuk L, da Silva LB, Haddad H: Enhanced external counterpulsation in ischemic heart disease and congestive heart failure. CMAJ 2004, 170:1223-1224.
• [8]Arora RR, Shah AG: Enhanced external counterpulsation: a new modality in the treatment of angina and heart failure. J Cardiovasc Pharmacol Ther 2006, 11:271-273.
• [9]Soran O: Treatment options for refractory angina pectoris: enhanced external counterpulsation therapy. Curr Treat Options Cardiovasc Med 2009, 11:54-60.
• [10]Stevens LA, Coresh J, Schmid CH, Feldman HI, Froissart M, Kusek J, Rossert J, Lente FV, Bruce RD III, Zhang YL, Greene T, Levey AS: Estimating GFR using serum cystatin C alone and in combination with serum creatinine: a pooled analysis of 3418 individuals with CKD. Am J Kidney Dis 2008, 51:395-406.
• [11]Werner D, Tragner P, Wawer A, Porst H, Daniel WG, Gross P: Enhanced external counterpulsation: a new technique to augment renal function in liver cirrhosis. Nephrol Dial Transplant 2005, 20:920-926.
• [12]National Kidney Foundation: K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis 2002, 39:S1-S266.
• [13]Hildebrandt P, Collinson PO: Amino-terminal pro–B-type natriuretic peptide testing to assist the diagnostic evaluation of heart failure in symptomatic primary care patients. Am J Cardiol 2008, 101(suppl):25A-28A.
• [14]Zaphiriou A, Robb S, Murray-Thomas T, Mendez G, Fox K, McDonagh T, Hardman SM, Dargie HJ, Cowie MR: The diagnostic accuracy of plasma BNP and NTproBNP in patients referred from primary care with suspected heart failure: results of the UK natriuretic peptide study. Eur J Heart Fail 2005, 7:537-541.
• [15]Silver MA: Mechanisms and evidence for the role of enhanced external counterpulsation in heart failure management. Curr Heart Fail Rep 2006, 3:25-32.
• [16]Manchanda A, Soran O: Enhanced external counterpulsation and future directions. J Am Coll Cardiol 2007, 50:1523-1531.
• [17]McCullough PA, Silver MA, Kennard ED, Kelsey SF, Michaels AD: Impact of body mass index on outcomes of enhanced external counterpulsation therapy. Am Heart J 2006, 151:139.e9-139.e13.
• [18]Feldman AM, Silver MA, Francis GS, Abbottsmith CW, Fleishman BL, Soran O, de Lame PA, Varricchione T: Enhanced external counterpulsation improves exercise tolerance in patients with chronic heart failure. J Am Coll Cardiol 2006, 48:1198-1205.
• [19]Loh PH, Cleland JGF, Louis AA, Kennard ED, Cook JF, Caplin JL, Barsness GW, Lawson WE, Soran OZ, Michaels AD: Enhanced external counterpulsation in the treatment of chronic refractory angina: a long-term follow-up outcome from the International Enhanced external counterpulsation Patient Registry. Clin Cardiol 2008, 31:159-164.
• [20]Werner D, Schneider M, Weise M, Nonnast-Daniel B, Daniel WG: Pneumatic external counterpulsation: a new noninvasive method to improve organ perfusion. Am J Cardiol 1999, 84:950-952.
• [21]Moertl D, Hammer A, Huelsmann M, Pacher R, Berger R: Prognostic value of sequential measurements of amino-terminal prohormone of B-type natriuretic peptide in ambulatory heart failure patients. Eur J Heart Fail 2008, 10:404-411.
• [22]DeFilippi CR, Christenson RH, Gottdiener JS, Kop WJ, Seliger SL: Dynamic cardiovascular risk assessment in elderly people. The role of repeated N-terminal pro-B-type natriuretic peptide testing. J Am Coll Cardiol 2010, 55:441-450.
• [23]Verdiani V, Ognibene A, Rutili MS, Lombardo C, Bacci F, Terreni A, Nozzoli C: NT-ProBNP reduction percentage during hospital stay predicts long-term mortality and readmission in heart failure patients. J Cardiovasc Med 2008, 9:694-699.
• [24]Bonetti PO, Holmes DR, Lerman A, Barsness GW: Enhanced external counterpulsation for ischemic heart disease. What’s behind the curtain? J Am Coll Cardiol 2003, 41:1918-1925.
• [25]Cohn PF: EECP-new data on possible mechanisms of action. Eur Heart J 2001, 22:1363-1364.
• [26]Fujita M: Angiogenic therapy by coronary collateral recruitment and arteriogenesis. In Myocardial ischemia and preconditioning. 1st edition. Edited by Dhalla NS, Takeda N, Singh M, Lukas A. Norwell, MA: Kluwer Academic Publishers; 2003:13-22.
• [27]Buschmann EE, Utz W, Pagonas N, Schulz-Menger J, Busjahn A, Monti J, Maerz W, le Noble F, Thierfelder L, Dietz R, Klauss V, Gross M, Buschmann IR: Improvement of fractional flow reserve and collateral flow by treatment with external counterpulsation (Art.Net.-2 Trial). Eur J Clin Invest 2009, 39:866-875.
• [28]Barsheshet A, Hod H, Shechter M, Sharabani-Yosef O, Rosenthal E, Barbash IM, Matetzky S, Tal R, Bentancur AG, Sela BA, Nagler A, Leor J: The effects of external counter pulsation therapy on circulating endothelial progenitor cells in patients with angina pectoris. Cardiology 2008, 110:160-166.
• [29]Wu G, Du Z, Hu C, Zheng Z, Zhan C, Ma H, Fang D, Ahmed KT, Laham RJ, Hui JCK, Lawson WE: Angiogenic effects of long-term enhanced external counterpulsation in a dog model of myocardial infarction. Am J Physiol Heart Circ Physiol 2006, 290:H248-H254.
• [30]Masuda D, Nohara R, Hirai T, Kataoka K, Chen LG, Hosokawa R, Inubushi M, Tadamura E, Fujita M, Sasayama S: Enhanced external counterpulsation improved myocardial perfusion and coronary flow reserve in patients with chronic stable angina. Eur Heart J 2001, 22:1451-1458.
• [31]Dharnidharka VR, Kwon C, Stevens G: Serum cystatin C is superior to serum creatinine as a marker of kidney function: a meta-analysis. Am J Kidney Dis 2002, 40:221-226.
• [32]Baxmann AC, Ahmed MS, Marques NC, Menon VB, Pereira AB, Kirsztajn GM, Heilberg IP: Influence of muscle mass and physical activity on serum and urinary creatinine and serum cystatin C. Clin J Am Soc Nephrol 2008, 3:348-354.
• [33]Séronie-Vivien S, Delanaye P, Piéroni L, Mariat C, Froissart M, Cristol JP: SFBC "Biology of renal function and renal failure" working group: csystatin C: current position and future prospects. Clin Chem Lab Med 2008, 46:1664-1686.
• [34]Perkins BA, Nelson RG, Ostrander BEP, Blouch KL, Krolewski AS, Myers BD, Warram JH: Detection of renal function decline in patients with diabetes and normal or elevated GFR by serial measurements of serum cystatin C concentration: results of a 4-year follow-up study. J Am Soc Nephrol 2005, 16:1404-1412.
• [35]Macdonald J, Marcora S, Jibani M, Roberts G, Mick Kumwenda M, Glover R, Barron J, Lemmey A: GFR estimation using cystatin C is not independent of body composition. Am J Kidney Dis 2006, 48:712-719.
• [36]Wiesli P, Schwegler B, Spinas GA, Schmid C: Serum cystatin C is sensitive to small changes in thyroid function. Clin Chim Acta 2003, 338:87-90.
• [37]Nakai K, Kikuchi M, Fujimoto K, Kaneko Y, Omori S, Nakai K, Suwabe A: Serum levels of cystatin C in patients with malignancy. Clin Exp Nephrol 2008, 12:132-139.
• [38]Patel PC, Ayers CR, Murphy SA, Peshock R, Khera A, de Lemos JA, Balko JA, Gupta S, Mammen PPA, Drazner MH, Markham DW: Association of cystatin C with left ventricular structure and function. The Dallas heart study. Circ Heart Fail 2009, 2:98-104.
• [39]Inker LA, Schmid CH, Tighiouart H, Eckfeldt JH MD, Feldman HI, Greene T, Kusek JW, Manzi J, Van Lente F, Lucy Zhang YL, Coresh J, Andrew L: Estimating glomerular filtration rate from serum creatinine and cystatin C. N Engl J Med 2012, 367:20-9.
• [40]Eknoyan G, Lameire N, Eckardt KU, Kasiske BL, Wheeler DC, Levin A, Stevens PE, Bilous RW, Lamb EJ, Coresh J, Levey AS, de Francisco ALM, Riella MC, de Jong PE, Shlipak MG, Griffith KE, Wang H, Hemmelgarn BR, White CT, Iseki K, Winearls CG: KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int 2013, Suppl 3:5-14.
• [41]Sikaneta T, Abdolell M, Taskapan H, Roscoe J, Fung J, Nagai G, Ting RH, Ng P, Wu G, Oreopoulos D, Tam PY: Variability in CKD stage in outpatients followed in two large renal clinics. Int Urol Nephrol 2012, 44:1461-1466.
• [42]Onuigbo MA, Onuigbo NT: Variability in CKD stage in outpatients followed in two large renal clinics: implications for CKD trials and the status of current knowledge of patterns of CKD to ESRD progression. Int Urol Nephrol 2012, 44:1589-1590.